David F. McDermott, MD

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the promise of single-agent pembrolizumab in advanced non–clear cell renal cell carcinoma.

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses single-agent versus combination immunotherapy in the treatment of patients with renal cell carcinoma.

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses single-agent pembrolizumab in the treatment of patients with advanced renal cell carcinoma.

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses an analysis of the CheckMate-214 study in advanced renal cell carcinoma (RCC).

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses novel immunotherapy combinations for patients with metastatic renal cell carcinoma (RCC).

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses immunotherapy as a standard of care for patients with renal cell carcinoma (RCC).

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses nivolumab (Opdivo) as a single-agent for the treatment of patients with renal cell carcinoma.

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in renal cell carcinoma (RCC).

David F. McDermott, MD, director, Biologic Therapy and Cutaneous Oncology Programs, Hematology/Oncology, Beth Israel Deaconess Medical Center, discusses the role of VEGF-targeted therapy in renal cell carcinoma.

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the immune-related toxicities for patients receiving checkpoint inhibitors for treatment of their renal cell carcinoma.

David F. McDermott, MD, Director of Biologic Therapy and Cutaneous Oncology Programs, Hematology and Oncology at the Beth Israel Deaconess Medical Center, discusses the combination of VEGF plus PD-1 in renal cell carcinoma (RCC).

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the findings of the phase III CheckMate-025 trial of nivolumab (Opdivo) versus everolimus (Afinitor) in renal cell carcinoma (RCC).

David F. McDermott, MD, associate professor of Medicine, Harvard Medical School, staff physician, director, Biologic Therapy and Cutaneous Oncology Programs, Hematology/Oncology, Beth Israel Deaconess Medical Center, discusses long-term follow-up results of treatment with nivolumab (Opdivo) for patients with renal cell carcinoma (RCC).